Home

Schering-Plough Corp.'s

An Ode to Schering-Plough

Thu, 11/05/2009 - 15:53 by Brian Orelli

We said goodbye to Wyeth three weeks ago,
Pfizer (NYSE: PFE) took it from our sight.
Today it's Schering-Plough's heave-ho,
Merck (NYSE: MRK) closed the deal last night.

Saphris OK'd for schizophrenia

Fri, 08/14/2009 - 22:00 by surajdogra

Washington -- Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S. authorities said.

The drug is to be made available later this year and marketed under the name
Saphris, the Food and Drug Administration said.

Saphris is the first psychotropic drug to receive initial approval to treat both mental disorders, Schering-Plough officials said.

Saphris is the first product from Schering-Plough's 2007 acquisition of Organon Biosciences. It's FDA approval comes as Schering-Plough prepares to merge with Merck & Co., The Wall Street Journal reported Friday.